134 related articles for article (PubMed ID: 12440170)
1. HIV genetic mutations causing resistance to the new drug T-20: recent findings.
Bean P
Am Clin Lab; 2002 Oct; 21(8):15-6. PubMed ID: 12440170
[No Abstract] [Full Text] [Related]
2. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
[No Abstract] [Full Text] [Related]
3. Preventing viral entry. Fusion inhibitors.
Marks N
Posit Living; 1999 Mar; 8(2):13. PubMed ID: 12491997
[No Abstract] [Full Text] [Related]
4. Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide.
Ueno M; Kodama EN; Shimura K; Sakurai Y; Kajiwara K; Sakagami Y; Oishi S; Fujii N; Matsuoka M
Antiviral Res; 2009 Apr; 82(1):67-72. PubMed ID: 19428597
[TBL] [Abstract][Full Text] [Related]
5. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM
Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
Antiviral Res; 2003 Jul; 59(2):137-42. PubMed ID: 12895697
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong.
Leung PH; Chen JH; Wong KH; Chan KC; Lam HY; Cheng VC; Yuen KY; Yam WC
J Clin Virol; 2010 Mar; 47(3):273-5. PubMed ID: 20116329
[TBL] [Abstract][Full Text] [Related]
8. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes.
Covens K; Kabeya K; Schrooten Y; Dekeersmaeker N; Van Wijngaerden E; Vandamme AM; De Wit S; Van Laethem K
J Clin Virol; 2009 Apr; 44(4):325-8. PubMed ID: 19237313
[TBL] [Abstract][Full Text] [Related]
9. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
10. Fusion inhibitors: T-20 and T-1249.
TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
[No Abstract] [Full Text] [Related]
11. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
Svicher V; Aquaro S; D'Arrigo R; Artese A; Dimonte S; Alcaro S; Santoro MM; Di Perri G; Caputo SL; Bellagamba R; Zaccarelli M; Visco-Comandini U; Antinori A; Narciso P; Ceccherini-Silberstein F; Perno CF
J Infect Dis; 2008 May; 197(10):1408-18. PubMed ID: 18419549
[TBL] [Abstract][Full Text] [Related]
12. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
[TBL] [Abstract][Full Text] [Related]
13. T-20--a fusion drug, first of several to come.
TreatmentUpdate; 1998 Dec; 10(10):2. PubMed ID: 11366015
[TBL] [Abstract][Full Text] [Related]
14. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
15. Genetic and structural analysis of HIV-1 Rev responsive element related to V38A and T18A enfuvirtide resistance mutations.
Dimonte S; Mercurio F; Svicher V; Perno CF; Ceccherini-Silberstein F
Intervirology; 2012; 55(5):385-90. PubMed ID: 22188777
[TBL] [Abstract][Full Text] [Related]
16. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
17. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
Baldwin CE; Sanders RW; Deng Y; Jurriaans S; Lange JM; Lu M; Berkhout B
J Virol; 2004 Nov; 78(22):12428-37. PubMed ID: 15507629
[TBL] [Abstract][Full Text] [Related]
18. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
[TBL] [Abstract][Full Text] [Related]
19. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
20. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
Morse C; Maldarelli F
J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
